Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial.

Kohei OtsuboJunji KishimotoMasahiko AndoHirotsugu Kenmotsu Yuji MinegishiHidehito HorinouchiTerufumi KatoEiki IchiharaMasashi KondoShinji AtagiMotohiro TamiyaSatoshi IkedaToshiyuki HaradaShinnosuke TakemotoHidetoshi HayashiKeita NakatomiYuichiro KimuraYasuhiro KondohMasahiko KusumotoKazuya IchikadoNobuyuki YamamotoKazuhiko NakagawaYoichi NakanishiIsamu Okamoto

Published in: The European respiratory journal (2022)

The primary end point of the study was not met. However, carboplatin plus nab-paclitaxel was found to be effective and tolerable in advanced NSCLC patients with IPF. Moreover, nintedanib in combination with such chemotherapy improved overall survival in patients with nonsquamous histology.

Keyphrases

idiopathic pulmonary fibrosis
interstitial lung disease
locally advanced
advanced non small cell lung cancer
small cell lung cancer
chemotherapy induced
phase ii study
rectal cancer
squamous cell carcinoma
rheumatoid arthritis
radiation therapy
systemic sclerosis
free survival
phase iii
brain metastases